Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 July 2002Next earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 02 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
MRKR Latest News
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. This conference will be held virtually on March 26, 2024.
Marker Therapeutics (NASDAQ: MRKR ) stock is rising higher on Wednesday as investors react to positive pre-clinical news from the clinical-stage immuno-oncology company. Today's results come from a test of MT-601 in lymphoma cells.
What type of business is Marker Therapeutics?
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
What sector is Marker Therapeutics in?
Marker Therapeutics is in the Healthcare sector
What industry is Marker Therapeutics in?
Marker Therapeutics is in the Biotechnology industry
What country is Marker Therapeutics from?
Marker Therapeutics is headquartered in United States
When did Marker Therapeutics go public?
Marker Therapeutics initial public offering (IPO) was on 16 July 2002
What is Marker Therapeutics website?
https://www.markertherapeutics.com
Is Marker Therapeutics in the S&P 500?
No, Marker Therapeutics is not included in the S&P 500 index
Is Marker Therapeutics in the NASDAQ 100?
No, Marker Therapeutics is not included in the NASDAQ 100 index
Is Marker Therapeutics in the Dow Jones?
No, Marker Therapeutics is not included in the Dow Jones index
When does Marker Therapeutics report earnings?
The next expected earnings date for Marker Therapeutics is 14 August 2024